

# Robert A Hauser

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5443797/robert-a-hauser-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

225  
papers

15,429  
citations

60  
h-index

121  
g-index

234  
ext. papers

17,822  
ext. citations

6.9  
avg, IF

6.34  
L-index

#	Paper	IF	Citations
225	Potential utility of amantadine DR/ER in persons with Parkinson's disease meeting 5-2-1 criteria for device aided therapy.. <i>Clinical Parkinsonism &amp; Related Disorders</i> , <b>2022</b> , 6, 100123	0.9	0
224	Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment.. <i>Neurology and Therapy</i> , <b>2022</b> ,	4.6	1
223	P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson's Disease.. <i>Advances in Therapy</i> , <b>2022</b> , 1	4.1	0
222	Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson's disease.. <i>Npj Parkinson's Disease</i> , <b>2022</b> , 8, 29	9.7	0
221	Minimal clinically important change in Abnormal Involuntary Movement Scale score in tardive dyskinesia as assessed in pivotal trials of deutetrabenazine.. <i>Parkinsonism and Related Disorders</i> , <b>2022</b> , 97, 47-51	3.6	0
220	Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee. <i>Neurology</i> , <b>2021</b> , 97, 942-957	6.5	11
219	Amantadine ER (Gocovri) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease. <i>Frontiers in Neurology</i> , <b>2021</b> , 12, 645706	4.1	6
218	Expediting telehealth use in clinical research studies: recommendations for overcoming barriers in North America. <i>Npj Parkinson's Disease</i> , <b>2021</b> , 7, 34	9.7	5
217	Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson's Disease and Dyskinesia. <i>Neurology and Therapy</i> , <b>2021</b> , 10, 307-320	4.6	2
216	Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson's Disease and Dyskinesia. <i>Neurology and Therapy</i> , <b>2021</b> , 10, 739-751	4.6	3
215	Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial. <i>Movement Disorders</i> , <b>2021</b> , 36, 2408-2412	7	1
214	On demand therapy for Parkinson's disease patients: Opportunities and choices. <i>Postgraduate Medicine</i> , <b>2021</b> , 133, 721-727	3.7	2
213	Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®). <i>Parkinsonism and Related Disorders</i> , <b>2021</b> , 82, 133-137	3.6	1
212	Sustained functional benefits after a single set of injections with abobotulinumtoxinA using a 2-mL injection volume in adults with cervical dystonia: 12-week results from a randomized, double-blind, placebo-controlled phase 3b study. <i>PLoS ONE</i> , <b>2021</b> , 16, e0245827	3.7	2
211	Real-World Experience with Carbidopa-Levodopa Extended-Release Capsules (Rytary): Results of a Nationwide Dose Conversion Survey. <i>Parkinson's Disease</i> , <b>2021</b> , 2021, 6638088	2.6	
210	Istradefylline - a first generation adenosine A antagonist for the treatment of Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , <b>2021</b> , 21, 317-333	4.3	13
209	Patterns and predictors of referrals to allied health services for individuals with Parkinson's disease: A Parkinson's foundation (PF) QII study. <i>Parkinsonism and Related Disorders</i> , <b>2021</b> , 83, 115-122	3.6	3

208	A Clinically Interpretable Computer-Vision Based Method for Quantifying Gait in Parkinson's Disease. <i>Sensors</i> , <b>2021</b> , 21,	3.8	6
207	Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 Trials. <i>Journal of Parkinson's Disease</i> , <b>2021</b> , 11, 1663-1675	5.3	4
206	Pimavanserin Treatment for Parkinson's Disease Psychosis in Clinical Practice. <i>Parkinson's Disease</i> , <b>2021</b> , 2021, 2603641	2.6	1
205	The challenge of developing adenosine A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant. <i>Parkinsonism and Related Disorders</i> , <b>2020</b> , 80 Suppl 1, S54-S63	3.6	10
204	Reply to: Letter to Editor by Chaudhuri, Jenner, Antonini. <i>Movement Disorders</i> , <b>2020</b> , 35, 901	7	
203	Parkinson Disease and Orthostatic Hypotension in the Elderly: Recognition and Management of Risk Factors for Falls <b>2020</b> , 11, 679-691		19
202	Carbidopa and Levodopa Extended Release Capsules in Patients with and without Troublesome and Non-Troublesome Dyskinesia. <i>Journal of Parkinson's Disease</i> , <b>2020</b> , 10, 915-925	5.3	0
201	Practical Evaluation and Management of Insomnia in Parkinson's Disease: A Review. <i>Movement Disorders Clinical Practice</i> , <b>2020</b> , 7, 250-266	2.2	11
200	EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , <b>2020</b> , 10, 543-558	5.3	12
199	Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice. <i>CNS Spectrums</i> , <b>2020</b> , 1-10	1.8	9
198	Dyskinesia matters. <i>Movement Disorders</i> , <b>2020</b> , 35, 392-396	7	24
197	Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Neurology</i> , <b>2020</b> , 19, 135-144	24.1	42
196	Duration of Symptom Relief Between Injections for AbobotulinumtoxinA (Dysport®) in Spastic Paresis and Cervical Dystonia: Comparison of Evidence From Clinical Studies. <i>Frontiers in Neurology</i> , <b>2020</b> , 11, 576117	4.1	7
195	134 Long-Term Deutetrabenazine Treatment Is Associated with Sustained Treatment Response in Tardive Dyskinesia: Results from an Open-Label Extension Study. <i>CNS Spectrums</i> , <b>2020</b> , 25, 284-285	1.8	1
194	Expanding phenomenologic heterogeneity of tardive syndromes: Time for an updated assessment tool. <i>Parkinsonism and Related Disorders</i> , <b>2020</b> , 77, 141-145	3.6	0
193	Medical Management and Prevention of Motor Complications in Parkinson's Disease. <i>Neurotherapeutics</i> , <b>2020</b> , 17, 1339-1365	6.4	15
192	A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2020</b> , 81, 144-150	3.6	5
191	Cognitive impairment in Parkinson's disease: Associations between subjective and objective cognitive decline in a large longitudinal study. <i>Parkinsonism and Related Disorders</i> , <b>2020</b> , 80, 127-132	3.6	3

190	Impact of non-motor symptoms in Parkinson's disease: a PMDAAlliance survey. <i>Neuropsychiatric Disease and Treatment</i> , <b>2019</b> , 15, 2205-2212	3.1	22
189	Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2019</b> , 90, 1317-1323	5.5	15
188	Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). <i>Parkinsonism and Related Disorders</i> , <b>2019</b> , 62, 201-209	3.6	9
187	Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials. <i>Journal of Parkinson's Disease</i> , <b>2019</b> , 9, 591-600	5.3	8
186	0617 Solriamfetol Treatment of Excessive Daytime Sleepiness in Parkinson's Disease: Results from a Phase 2 Proof-of-Concept Trial. <i>Sleep</i> , <b>2019</b> , 42, A245-A246	1.1	
185	34 Long-Term Deutetrabenazine Treatment Response in Tardive Dyskinesia by Concomitant Dopamine-Receptor Antagonists and Baseline Comorbidities. <i>CNS Spectrums</i> , <b>2019</b> , 24, 193-193	1.8	
184	45 Long-term Treatment with Deutetrabenazine Is Associated with Continued Improvement in Tardive Dyskinesia: Results from an Open-label Extension Study. <i>CNS Spectrums</i> , <b>2019</b> , 24, 200-201	1.8	2
183	46 Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-label Extension Study. <i>CNS Spectrums</i> , <b>2019</b> , 24, 201-201	1.8	1
182	35 Long-term Improvements in Site-Rated Outcomes with Deutetrabenazine Treatment in Patients with Tardive Dyskinesia. <i>CNS Spectrums</i> , <b>2019</b> , 24, 193-194	1.8	
181	Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2019</b> , 64, 175-180	3.6	23
180	Pharmacokinetics of ADS-5102 (Amantadine) Extended-Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia. <i>Clinical Pharmacokinetics</i> , <b>2019</b> , 58, 77-88	6.2	27
179	Targeting neurons in the gastrointestinal tract to treat Parkinson's disease. <i>Clinical Parkinsonism &amp; Related Disorders</i> , <b>2019</b> , 1, 2-7	0.9	9
178	Higher neuron densities in the cerebral cortex and larger cerebellums may limit dive times of delphinids compared to deep-diving toothed whales. <i>PLoS ONE</i> , <b>2019</b> , 14, e0226206	3.7	5
177	Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Neurology</i> , <b>2019</b> , 18, 145-154	24.1	52
176	The nosology of tardive syndromes. <i>Journal of the Neurological Sciences</i> , <b>2018</b> , 389, 10-16	3.2	42
175	Tardive dyskinesia: Out of the shadows. <i>Journal of the Neurological Sciences</i> , <b>2018</b> , 389, 1-3	3.2	18
174	A 500U/2mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia. <i>International Journal of Neuroscience</i> , <b>2018</b> , 128, 619-626	2	8
173	Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson's disease. <i>Neuropsychiatric Disease and Treatment</i> , <b>2018</b> , 14, 839-845	3.1	8

172	149 Deutetrabenazine for the Treatment of Tardive Dyskinesia: Results From an Open-Label, Long-Term Study. <i>CNS Spectrums</i> , <b>2018</b> , 23, 92-93	1.8	
171	134 Improvements in Clinical Global Impression of Change With Deutetrabenazine Treatment in Tardive Dyskinesia From the ARM-TD and AIM-TD Studies. <i>CNS Spectrums</i> , <b>2018</b> , 23, 84-84	1.8	
170	158 Long-Term Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia: Results From an Open-Label, Long-Term Study. <i>CNS Spectrums</i> , <b>2018</b> , 23, 97-97	1.8	
169	Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. <i>Nature Reviews Drug Discovery</i> , <b>2018</b> , 17, 804-822	64.1	114
168	Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson Disease. <i>Movement Disorders Clinical Practice</i> , <b>2018</b> , 5, 627-634	2.2	12
167	Help cure Parkinson's disease: please don't waste the Golden Year. <i>Npj Parkinson's Disease</i> , <b>2018</b> , 4, 29	9.7	0
166	Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials. <i>Annals of Pharmacotherapy</i> , <b>2018</b> , 52, 1182-1194	2.9	15
165	Cardiovascular Safety of Droxidopa in Patients With Symptomatic Neurogenic Orthostatic Hypotension. <i>American Journal of Cardiology</i> , <b>2017</b> , 119, 1111-1115	3	13
164	Caffeine, creatine, GRIN2A and Parkinson's disease progression. <i>Journal of the Neurological Sciences</i> , <b>2017</b> , 375, 355-359	3.2	17
163	Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort. <i>Journal of the Neurological Sciences</i> , <b>2017</b> , 377, 137-143	3.2	19
162	Randomized trial of praladenant, given as monotherapy, in patients with early Parkinson disease. <i>Neurology</i> , <b>2017</b> , 88, 2198-2206	6.5	41
161	Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. <i>Neurology</i> , <b>2017</b> , 88, 2003-2010	6.5	184
160	ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial. <i>JAMA Neurology</i> , <b>2017</b> , 74, 941-949	17.2	112
159	A randomized trial of a low-dose Rasagiline and Pramipexole combination (P2B001) in early Parkinson's disease. <i>Movement Disorders</i> , <b>2017</b> , 32, 783-789	7	16
158	KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. <i>American Journal of Psychiatry</i> , <b>2017</b> , 174, 476-484	11.9	209
157	Design of a cluster-randomized minority recruitment trial: RECRUIT. <i>Clinical Trials</i> , <b>2017</b> , 14, 286-298	2.2	18
156	Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An Analysis of NET-PD LS1. <i>Journal of Parkinson's Disease</i> , <b>2017</b> , 7, 117-127	5.3	15
155	Use, maintenance and dose effects of cognitive speed of processing training in Parkinson's disease. <i>International Journal of Neuroscience</i> , <b>2017</b> , 127, 841-848	2	5

154	Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. <i>JAMA Neurology</i> , <b>2017</b> , 74, 216-224	17.2	116
153	Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease. <i>Journal of the Neurological Sciences</i> , <b>2017</b> , 373, 116-123	3.2	6
152	ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study. <i>Journal of Parkinson's Disease</i> , <b>2017</b> , 7, 511-522	5.3	37
151	Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3). <i>Movement Disorders</i> , <b>2017</b> , 32, 1701-1709	7.0	103
150	Valbenazine for the treatment of tardive dyskinesia. <i>Expert Opinion on Pharmacotherapy</i> , <b>2017</b> , 18, 1279-1287	4.6	6
149	ADS-5102 (Amantadine) Extended Release for Levodopa-Induced Dyskinesia. <i>JAMA Neurology</i> , <b>2017</b> , 74, 1507-1508	17.2	11
148	Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double-blind, placebo-controlled multicenter study. <i>Movement Disorders</i> , <b>2017</b> , 32, 1335-1336	7.0	9
147	A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III). <i>Annals of Clinical and Translational Neurology</i> , <b>2017</b> , 4, 360-368	5.3	46
146	Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Psychiatry</i> , <b>2017</b> , 4, 595-604	23.3	174
145	Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease. <i>Movement Disorders</i> , <b>2016</b> , 31, 1366-72	7.0	54
144	Communicating with participants during the conduct of multi-center clinical trials. <i>Clinical Trials</i> , <b>2016</b> , 13, 592-596	2.2	4
143	Long-term effects of rasagiline and the natural history of treated Parkinson's disease. <i>Movement Disorders</i> , <b>2016</b> , 31, 1489-1496	7.0	35
142	A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease. <i>Movement Disorders</i> , <b>2016</b> , 31, 1356-65	7.0	61
141	Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1. <i>Parkinsonism and Related Disorders</i> , <b>2016</b> , 33, 127-133	3.6	6
140	Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension. <i>Clinical Neuropharmacology</i> , <b>2016</b> , 39, 220-6	1.4	35
139	Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. <i>JAMA Neurology</i> , <b>2016</b> , 73, 102-110	17.2	29
138	α-Synuclein in Parkinson's disease: getting to the core of the matter. <i>Lancet Neurology</i> , <b>2015</b> , 14, 785-786	24.1	4
137	Initial choice of medication has little effect on short-term or long-term outcome for most patients with Parkinson's disease. <i>Evidence-Based Medicine</i> , <b>2015</b> , 20, 17		2

136	NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. <i>Movement Disorders</i> , <b>2015</b> , 30, 1681-7	7	82
135	Carbidopa levodopa enteral suspension. <i>Expert Opinion on Pharmacotherapy</i> , <b>2015</b> , 16, 2807-17	4	13
134	Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B). <i>Movement Disorders</i> , <b>2015</b> , 30, 646-54	7	105
133	Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. <i>Lancet Neurology</i> , <b>2014</b> , 13, 767-76	24.1	97
132	Minimal clinically important difference in Parkinson's disease as assessed in pivotal trials of pramipexole extended release. <i>Parkinson's Disease</i> , <b>2014</b> , 2014, 467131	2.6	44
131	A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. <i>JAMA Neurology</i> , <b>2014</b> , 71, 543-52	17.2	239
130	An update on Parkinson's disease: improving patient outcomes. <i>American Journal of Medicine</i> , <b>2014</b> , 127, S3	2.4	18
129	Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. <i>Lancet Neurology</i> , <b>2013</b> , 12, 346-56	24.1	149
128	[123I]FP-CIT (DaTscan) SPECT brain imaging in patients with suspected parkinsonian syndromes. <i>Journal of Neuroimaging</i> , <b>2012</b> , 22, 225-30	2.8	40
127	Head injury, Bsynuclein Rep1, and Parkinson's disease. <i>Annals of Neurology</i> , <b>2012</b> , 71, 40-8	9.4	66
126	The UPDRS-8: a brief clinical assessment scale for Parkinson's disease. <i>International Journal of Neuroscience</i> , <b>2012</b> , 122, 333-7	2	3
125	Efficacy, tolerability, and immunogenicity of onabotulinumtoxinA in a randomized, double-blind, placebo-controlled trial for cervical dystonia. <i>Clinical Neuropharmacology</i> , <b>2012</b> , 35, 208-14	1.4	54
124	Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). <i>Neurology</i> , <b>2012</b> , 79, 163-9	6.5	77
123	IPX066: a novel carbidopa-levodopa extended-release formulation. <i>Expert Review of Neurotherapeutics</i> , <b>2012</b> , 12, 133-40	4.3	18
122	Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and L-dopa-undertreated Parkinson disease: a double-blind, randomized trial. <i>Clinical Neuropharmacology</i> , <b>2012</b> , 35, 174-81	1.4	29
121	Future treatments for Parkinson's disease: surfing the PD pipeline. <i>International Journal of Neuroscience</i> , <b>2011</b> , 121 Suppl 2, 53-62	2	45
120	The Parkinson Progression Marker Initiative (PPMI). <i>Progress in Neurobiology</i> , <b>2011</b> , 95, 629-35	10.9	793
119	Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. <i>Lancet Neurology</i> , <b>2011</b> , 10, 221-9	24.1	159

118	A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. <i>Lancet Neurology, The</i> , <b>2011</b> , 10, 415-23	24.1	159
117	Intrastratial transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson's disease: a double-blind, randomised, controlled trial. <i>Lancet Neurology, The</i> , <b>2011</b> , 10, 509-19	24.1	122
116	Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials. <i>Movement Disorders</i> , <b>2011</b> , 26, 1464-76	7	32
115	Determination of minimal clinically important change in early and advanced Parkinson's disease. <i>Movement Disorders</i> , <b>2011</b> , 26, 813-8	7	107
114	Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease. <i>Movement Disorders</i> , <b>2011</b> , 26, 2246-52	7	77
113	Wearing-off scales in Parkinson's disease: critique and recommendations. <i>Movement Disorders</i> , <b>2011</b> , 26, 2169-75	7	68
112	Long-term, open-label study of once-daily ropinirole prolonged release in early Parkinson's disease. <i>International Journal of Neuroscience</i> , <b>2011</b> , 121, 246-53	2	15
111	Long-term efficacy of rasagiline in early Parkinson's disease. <i>International Journal of Neuroscience</i> , <b>2010</b> , 120, 404-8	2	22
110	Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects. <i>Clinical Neuropharmacology</i> , <b>2010</b> , 33, 5-10	1.4	33
109	The independent influence of apathy and depression on cognitive functioning in Parkinson's disease. <i>Neuropsychology</i> , <b>2010</b> , 24, 721-30	3.8	62
108	Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. <i>Movement Disorders</i> , <b>2010</b> , 25, 858-66	7	66
107	Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease. <i>Movement Disorders</i> , <b>2010</b> , 25, 738-46	7	27
106	Reply: Intravenous glutathione in Parkinson's disease. <i>Movement Disorders</i> , <b>2010</b> , 25, 962-963	7	
105	Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations. <i>Movement Disorders</i> , <b>2010</b> , 25, 927-31	7	10
104	Task force report on scales to assess dyskinesia in Parkinson's disease: critique and recommendations. <i>Movement Disorders</i> , <b>2010</b> , 25, 1131-42	7	75
103	Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson's disease. <i>Movement Disorders</i> , <b>2010</b> , 25, 2326-32	7	30
102	Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. <i>Movement Disorders</i> , <b>2010</b> , 25, 2542-9	7	69
101	Treatment of early Parkinson's disease. Part 1. <i>European Neurology</i> , <b>2009</b> , 61, 193-205	2.1	10



100	Treatment of early Parkinson's disease. Part 2. <i>European Neurology</i> , <b>2009</b> , 61, 206-15	2.1	10
99	Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. <i>Movement Disorders</i> , <b>2009</b> , 24, 541-50	7	99
98	Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. <i>Movement Disorders</i> , <b>2009</b> , 24, 979-83	7	96
97	Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. <i>Movement Disorders</i> , <b>2009</b> , 24, 564-73	7	108
96	Levodopa response in early Parkinson's disease. <i>Movement Disorders</i> , <b>2009</b> , 24, 2328-36	7	36
95	A double-blind, delayed-start trial of rasagiline in Parkinson's disease. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 1268-78	59.2	694
94	Levodopa: past, present, and future. <i>European Neurology</i> , <b>2009</b> , 62, 1-8	2.1	114
93	New considerations in the medical management of early Parkinson's disease: impact of recent clinical trials on treatment strategy. <i>Parkinsonism and Related Disorders</i> , <b>2009</b> , 15 Suppl 3, S17-21	3.6	19
92	Fentanyl-induced bradykinesia and rigidity after deep brain stimulation in a patient with Parkinson disease. <i>Clinical Neuropharmacology</i> , <b>2009</b> , 32, 48-50	1.4	18
91	Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. <i>Nature Medicine</i> , <b>2008</b> , 14, 504-6	50.5	1209
90	Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments. <i>European Neurology</i> , <b>2008</b> , 60, 57-66	2.1	55
89	Delayed thalamic intracranial hemorrhage in an essential tremor patient following deep brain stimulation. <i>European Neurology</i> , <b>2008</b> , 59, 187-9	2.1	9
88	Caffeine and progression of Parkinson disease. <i>Clinical Neuropharmacology</i> , <b>2008</b> , 31, 189-96	1.4	30
87	Levetiracetam for stiff-person syndrome: report of 2 patients. <i>Clinical Neuropharmacology</i> , <b>2008</b> , 31, 301-2	1.4	2
86	Chorea as a side effect of gabapentin (Neurontin) in a patient with complex regional pain syndrome Type 1. <i>Clinical Rheumatology</i> , <b>2008</b> , 27, 389-90	3.9	10
85	Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. <i>Movement Disorders</i> , <b>2008</b> , 23, 690-9	7	187
84	Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. <i>Movement Disorders</i> , <b>2008</b> , 23, 2177-85	7	174
83	A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. <i>Movement Disorders</i> , <b>2008</b> , 23, 2194-201	7	138

82	Transplanted dopaminergic neurons develop PD pathologic changes: a second case report. <i>Movement Disorders</i> , <b>2008</b> , 23, 2303-6	7	212
81	Pregabalin (Lyrica) in the treatment of essential tremor. <i>Movement Disorders</i> , <b>2007</b> , 22, 139-41	7	17
80	Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease. <i>Movement Disorders</i> , <b>2007</b> , 22, 359-65	7	42
79	A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor. <i>Movement Disorders</i> , <b>2007</b> , 22, 279-82	7	74
78	Tiagabine and exacerbation of essential tremor. <i>Movement Disorders</i> , <b>2007</b> , 22, 2132-3	7	8
77	A pilot, double-blind, placebo-controlled trial of pregabalin (Lyrica) in the treatment of essential tremor. <i>Movement Disorders</i> , <b>2007</b> , 22, 1660-3	7	54
76	Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. <i>Movement Disorders</i> , <b>2007</b> , 22, 2409-17	7	174
75	Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment. <i>Current Neurology and Neuroscience Reports</i> , <b>2007</b> , 7, 302-10	6.6	31
74	Role of the pharmacist in the effective management of wearing-off in Parkinson's disease. <i>Annals of Pharmacotherapy</i> , <b>2007</b> , 41, 1842-9	2.9	10
73	Advances in the pharmacologic management of early Parkinson disease. <i>Neurologist</i> , <b>2007</b> , 13, 126-32	1.6	23
72	Prevalence and treatment of non-motor symptoms in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2007</b> , 13, 545	3.6	19
71	Optimizing bioavailability in the treatment of Parkinson's disease. <i>Neuropharmacology</i> , <b>2007</b> , 53, 791-800.5	0.5	18
70	Duodenal levodopa infusion for the treatment of Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2007</b> , 8, 657-64	4	40
69	Treatment of chorea with levetiracetam. <i>European Journal of Clinical Pharmacology</i> , <b>2006</b> , 62, 87	2.8	5
68	Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease. <i>Movement Disorders</i> , <b>2006</b> , 21, 115-6	7	57
67	Vascular hemichorea/hemiballismus and topiramate. <i>Movement Disorders</i> , <b>2006</b> , 21, 581; author reply 582	7	3
66	Use of nutritional supplements in Parkinson's disease patients. <i>Movement Disorders</i> , <b>2006</b> , 21, 1098-101	7	17
65	Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease. <i>Movement Disorders</i> , <b>2006</b> , 21, 1998-2001	7	24

64	Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. <i>Archives of Neurology</i> , <b>2006</b> , 63, 1756-60		137
63	Long-term evaluation of deep brain stimulation of the thalamus. <i>Journal of Neurosurgery</i> , <b>2006</b> , 104, 506-12	3.2	259
62	Deep brain stimulation of the internal segment of the globus pallidus in delayed runaway dyskinesia. <i>Archives of Neurology</i> , <b>2006</b> , 63, 1181-4		24
61	End-of-dose wearing off in Parkinson disease: a 9-question survey assessment. <i>Clinical Neuropharmacology</i> , <b>2006</b> , 29, 312-21	1.4	54
60	The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status. <i>Clinical Neuropharmacology</i> , <b>2006</b> , 29, 106-114	1.4	29
59	Patient evaluation of a home diary to assess duration and severity of dyskinesia in Parkinson disease. <i>Clinical Neuropharmacology</i> , <b>2006</b> , 29, 322-30	1.4	22
58	Topiramate-induced psychosis in patients with essential tremor: report of 2 cases. <i>Clinical Neuropharmacology</i> , <b>2006</b> , 29, 168-9	1.4	10
57	Clinical trials aimed at detecting neuroprotection in Parkinson's disease. <i>Neurology</i> , <b>2006</b> , 66, S58-68	6.5	15
56	Levetiracetam for the treatment of generalized dystonia. <i>Parkinsonism and Related Disorders</i> , <b>2005</b> , 11, 469-71	3.6	19
55	Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience. <i>Drugs and Aging</i> , <b>2005</b> , 22, 471-82	4.7	46
54	Levetiracetam-induced parkinsonism in a Huntington disease patient. <i>Clinical Neuropharmacology</i> , <b>2005</b> , 28, 188-90	1.4	15
53	Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. <i>Movement Disorders</i> , <b>2005</b> , 20, 726-33	7	186
52	Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. <i>Movement Disorders</i> , <b>2005</b> , 20, 783-91	7	210
51	Chorea in a patient with cerebral palsy: treatment with levetiracetam. <i>Movement Disorders</i> , <b>2005</b> , 20, 762-4	7	14
50	Levetiracetam for the treatment of essential tremor. <i>Movement Disorders</i> , <b>2005</b> , 20, 640	7	6
49	Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease. <i>Movement Disorders</i> , <b>2005</b> , 20, 1205-9	7	60
48	Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. <i>Movement Disorders</i> , <b>2004</b> , 19, 426-32	7	128
47	Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. <i>Movement Disorders</i> , <b>2004</b> , 19, 916-23	7	97

46	Substantial improvement in a Meige's syndrome patient with levetiracetam treatment. <i>Movement Disorders</i> , <b>2004</b> , 19, 1518-21	7	21
45	Parkinson's disease home diary: further validation and implications for clinical trials. <i>Movement Disorders</i> , <b>2004</b> , 19, 1409-13	7	136
44	Botulinum toxin A for the treatment of cervical dystonia. <i>Expert Opinion on Pharmacotherapy</i> , <b>2004</b> , 5, 2017-24	4	9
43	Future therapies for Parkinson's disease. <i>Neurologic Clinics</i> , <b>2004</b> , 22, S149-66	4.5	2
42	Essential tremor. Epidemiology, diagnosis, and treatment. <i>Neurologist</i> , <b>2004</b> , 10, 250-8	1.6	36
41	Levodopa/carbidopa/entacapone (Stalevo). <i>Neurology</i> , <b>2004</b> , 62, S64-71	6.5	42
40	Translocation breakpoint in two unrelated Tourette syndrome cases, within a region previously linked to the disorder. <i>Human Genetics</i> , <b>2003</b> , 113, 154-61	6.3	21
39	Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. <i>Annals of Neurology</i> , <b>2003</b> , 54, 93-101	9.4	691
38	Sleep attacks and dopamine agonists for Parkinson's disease: what is currently known?. <i>CNS Drugs</i> , <b>2003</b> , 17, 593-600	6.7	11
37	Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. <i>Neurology</i> , <b>2003</b> , 61, 297-303	6.5	264
36	Demonstration of a sensory trick in a case of writer's cramp. <i>Movement Disorders</i> , <b>2002</b> , 17, 427-427	7	2
35	Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease. <i>Movement Disorders</i> , <b>2002</b> , 17, 961-8	7	59
34	Clozapine withdrawal symptoms in a Parkinson's disease patient. <i>Movement Disorders</i> , <b>2002</b> , 17, 1365-7	7	16
33	Bilateral human fetal striatal transplantation in Huntington's disease. <i>Neurology</i> , <b>2002</b> , 58, 1704; author reply 1704	6.5	24
32	Neurosurgery for Parkinson's disease. <i>Seminars in Neurology</i> , <b>2001</b> , 21, 91-101	3.2	11
31	Phenomenology and treatment of tremor disorders. <i>Neurologic Clinics</i> , <b>2001</b> , 19, 651-80, vii	4.5	29
30	Transplantation of human fetal striatal tissue in Huntington's disease: rationale for clinical studies. <i>Novartis Foundation Symposium</i> , <b>2000</b> , 231, 129-38; discussion 139-47		17
29	A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. <i>Clinical Neuropharmacology</i> , <b>2000</b> , 23, 75-81	1.4	182

28	Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson's disease. <i>Movement Disorders</i> , <b>2000</b> , 15, 305-8	7	113
27	Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease. <i>Movement Disorders</i> , <b>2000</b> , 15, 485-489	7	54
26	Pramipexole-induced somnolence and episodes of daytime sleep. <i>Movement Disorders</i> , <b>2000</b> , 15, 658-637		187
25	Adult Chediak-Higashi parkinsonian syndrome with dystonia. <i>Movement Disorders</i> , <b>2000</b> , 15, 705-8	7	27
24	Modafinil treatment of pramipexole-associated somnolence. <i>Movement Disorders</i> , <b>2000</b> , 15, 1269-71	7	47
23	Depression in Patients with Parkinson's Disease. <i>CNS Drugs</i> , <b>2000</b> , 13, 253-264	6.7	3
22	Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease. <i>New England Journal of Medicine</i> , <b>1999</b> , 341, 988-92	59.2	177
21	Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. <i>Archives of Neurology</i> , <b>1999</b> , 56, 179-87		292
20	Management of early Parkinson's disease. <i>Medical Clinics of North America</i> , <b>1999</b> , 83, 393-414, vi	7	9
19	Plasma thiamine deficiency associated with Alzheimer's disease but not Parkinson's disease. <i>Metabolic Brain Disease</i> , <b>1998</b> , 13, 43-53	3.9	41
18	Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. <i>Movement Disorders</i> , <b>1998</b> , 13, 383-93	7	232
17	A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group. <i>Movement Disorders</i> , <b>1998</b> , 13, 643-7	7	39
16	Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil. <i>Neurology</i> , <b>1998</b> , 51, 912-3	6.5	46
15	Hyperactivity and hypoactivity in a rat model of Huntington's disease: the systemic 3-nitropropionic acid model. <i>Brain Research Protocols</i> , <b>1997</b> , 1, 253-7		48
14	Article Commentary: Infectious Issues in Human Fetal Neural Transplantation. <i>Cell Transplantation</i> , <b>1997</b> , 6, 553-556	4	11
13	High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. <i>Annals of Neurology</i> , <b>1997</b> , 42, 292-9	9.4	451
12	Sertraline for the treatment of depression in Parkinson's disease. <i>Movement Disorders</i> , <b>1997</b> , 12, 756-9	7	124
11	Cyclosporine-A increases locomotor activity in rats with 6-hydroxydopamine-induced hemiparkinsonism: relevance to neural transplantation. <i>World Neurosurgery</i> , <b>1996</b> , 46, 384-8		19

10	Blood manganese correlates with brain magnetic resonance imaging changes in patients with liver disease. <i>Canadian Journal of Neurological Sciences</i> , <b>1996</b> , 23, 95-8	1	87
9	Magnetic resonance imaging of corticobasal degeneration <b>1996</b> , 6, 222-6		50
8	Manganese and chronic liver disease. <i>Movement Disorders</i> , <b>1996</b> , 11, 589	7	7
7	Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. <i>New England Journal of Medicine</i> , <b>1995</b> , 332, 1118-24	59.2	764
6	Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. <i>Annals of Neurology</i> , <b>1995</b> , 38, 379-88	9.4	370
5	Sertraline-induced exacerbation of tics in Tourette's syndrome. <i>Movement Disorders</i> , <b>1995</b> , 10, 682-4	7	20
4	Manganese intoxication and chronic liver failure. <i>Annals of Neurology</i> , <b>1994</b> , 36, 871-5	9.4	204
3	Magnetic resonance imaging of neurodegenerative diseases <b>1994</b> , 4, 146-58		11
2	Orobuccal dyskinesia associated with trihexyphenidyl therapy in a patient with Parkinson's disease. <i>Movement Disorders</i> , <b>1993</b> , 8, 512-4	7	29
1	Hypertensive encephalopathy. Magnetic resonance imaging demonstration of reversible cortical and white matter lesions. <i>Archives of Neurology</i> , <b>1988</b> , 45, 1078-83		177